Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1661181 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.52Day −0.40%Mkt cap $324MP/E (FY) 16.8×1Y −47.2%Off 52W high −64.4%Vol (1Y) 74.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,390 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.2% of sh out |
| Days to cover16.9d |
| 13F net flow (QoQ)−4.04% |
| Top-10 13F concentration70.7% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)16.8× |
| Sales (TTM)$514.7M |
| Earnings (TTM)$2.7M |
| ROE13.2% |
| Net margin6.6% |
| ROIC21.1% |
| EPS growth 3Y7.7% |
| Sales growth 3Y7.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−51.4% |
| 1Y−47.2% |
| 3Y−41.0% |
| 5Y−83.6% |
| Since incept. (ann.)−13.2% |
Total return through 2026-07-29 · series begins 2017-01-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)74.3% |
| Ann. volatility (3Y)100.8% |
| Sharpe (1Y)−0.60 |
| Sharpe (3Y)0.26 |
| Max drawdown (1Y)−65.7% |
| Max drawdown (3Y)−65.7% |
| Beta (3Y vs SPY)1.86 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| MORGAN STANLEY | 11.6M | $28M | 9.03% | −0.2% |
| Soleus Capital Management, L.P. | 10.1M | $24M | 7.84% | +1.0% |
| BlackRock, Inc. | 4.9M | $12M | 3.81% | +2.9% |
| First Light Asset Management, LLC | 3.5M | $8M | 2.72% | −9.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $7M | 2.25% | new |
| DIMENSIONAL FUND ADVISORS LP | 2.9M | $7M | 2.25% | +5.9% |
| D. E. Shaw & Co., Inc. | 2.3M | $5M | 1.79% | +15.6% |
| Assenagon Asset Management S.A. | 2.0M | $5M | 1.53% | −64.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.44 | — | $37.2M | −57.1% |
| 2025-12-31 | 2026-02-26 | — | — | $225.6M | +78.1% |
| 2025-09-30 | 2025-11-06 | $0.11 | +22.2% | $150.9M | +31.0% |
| 2025-06-30 | 2025-08-07 | −$0.10 | — | $101.0M | −22.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 100% · Grant 0%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
